Abingdon Health Plc
ABDXF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.71 | 0.08 | 0.07 |
| FCF Yield | -13.57% | -2.82% | -7.21% | -6.53% |
| EV / EBITDA | -8.75 | -16,517.77 | -34.88 | -77.35 |
| Quality | ||||
| ROIC | -32.59% | -1.75% | -60.32% | -27.44% |
| Gross Margin | 30.59% | 64.46% | -17.59% | 49.22% |
| Cash Conversion Ratio | 1.06 | 6.97 | 0.97 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.85% | 6.11% | 1.91% | 14.81% |
| Free Cash Flow Growth | -464.44% | 60.08% | -9.23% | -156.42% |
| Safety | ||||
| Net Debt / EBITDA | 1.36 | 391.00 | 2.21 | 11.79 |
| Interest Coverage | -52.77 | -8.94 | -51.32 | -30.10 |
| Efficiency | ||||
| Inventory Turnover | 4.30 | 3.00 | 3.45 | 4.53 |
| Cash Conversion Cycle | -47.07 | 23.69 | -26.31 | -25.79 |